Vilka är öppettiderna?

Måndag 09:00 - 17:00 Tisdag 09:00 - 17:00 Onsdag 09:00 - 17:00 Torsdag 09:00 - 17:00 Fredag 09:00 - 17:00

AMRA Medical

Hem
Sverige
Linköping
AMRA Medical

Our Vision is a new, fundamental way of thinking about health.

We leverage our proprietary MRI body composition analytics and deep expertise in disease research to deliver precise biomarkers – extracting insights from within your research or patient data to enhance your drug trial or clinical decision-making. AMRA is the first in the world to transform MR images into precise body composition measurements using a cloud-based, computer-aided service and a rapid

MRI scan. Our imaging-based biomarkers (visceral fat, abdominal subcutaneous fat, liver fat, intramuscular fat, muscle group volumes, single muscle volumes, etc) are designed to play a long-term role in clinical trial development, research studies, and preventive care in a clinical setting. We collaborate with world-leading pharma, biobanks, research institutions, and hospitals, aiding in the advancement of metabolic research and its therapeutic application. With accurate knowledge about our bodies, we assist global medical leaders in predicting and preventing illnesses related to obesity-related and other metabolic disease, including diabetes, obesity, cardiovascular disease, liver disease, sarcopenia, musculoskeletal disorders, and more. We provide knowledge to the medical community so that every individual can become — and stay — healthy.

28/05/2026

Muscles, Metabolic Surgery, and MASLD: AMRA Medical to Highlight Latest Research Exploring the Connection Between at EASL 2026

AMRA is at the 2026 EASL Congress in Barcelona, Spain to present new findings exploring the impact of metabolic surgery on muscle composition in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The poster presentation, titled “Impact of metabolic surgery on muscle composition in patients with MASLD: A longitudinal MRI study,” highlights how MRI-based measures can provide a more comprehensive understanding of treatment effects beyond weight loss.

Conducted in collaboration with researchers from the University of Wisconsin-Madison and the University of California San Diego led by principal investigators Scott Reeder, MD, PhD and Claude Sirlin, and with Regeneron Pharmaceuticals, the longitudinal study assessed changes in muscle quantity and quality among adults with obesity undergoing metabolic and bariatric surgery. Using AMRA® Researcher, investigators quantified thigh muscle volume, muscle fat infiltration, intramuscular fat volume, and personalized muscle volume z-scores across five MRI visits spanning pre-surgery through one year post-operation.

Read more about the findings here: https://amramedical.com/muscles-metabolic-surgery-and-masld-amra-medical-to-highlight-latest-research-exploring-the-connection-between-at-easl-2026/

Are you attending the 2026 EASL Congress? We want to meet you! Make sure to stop by our poster tomorrow in Hall 7, from 8:30-17:00 and meet Jennifer Linge, Mikael Forsgren and Andrea Robina Galatas.

25/05/2026

We’re excited to be part of the conversation at the 2026 EASL Congress in Barcelona, Spain! This year, AMRA Medical will present new research exploring the connection between metabolic surgery, muscle composition, and MASLD, highlighting how MRI-based assessments can provide a more comprehensive understanding of treatment effects beyond conventional measures such as body weight or BMI.

Be sure to stop by our poster, “Impact of metabolic surgery on muscle composition in patients with MASLD: A longitudinal MRI study,” during the poster sessions in Hall 7, running from 8:30–17:00 on May 29.

We’d love the opportunity to connect with colleagues across the liver health and disease space to discuss how AMRA’s MRI-based fat distribution and muscle composition technologies are helping advance clinical research in liver disease and beyond.

If you’ll be attending EASL 2026 and would be interested in setting up a time to connect, please reach out to [email protected] — we look forward to meeting you in Spain!

07/05/2026

Can MSK MRI help drive impact in population health? Come find out at ISMRM 2026!

AMRA is looking forward to touching down in Cape Town this weekend to take part in the 2026 edition of the ISMRM Annual Meeting, which runs from May 9-14! We are especially excited given that on Saturday, May 9, AMRA’s own Per Widholm will deliver an invited lecture during the “History of MSK MRI: Past, Present, and Future” session. His talk, “Future: Role of MSK MRI in population health,” addresses the need for a shift in clinical MSK MRI practice.

Per will discuss how a transition toward using standardized and reproducible quantitative biomarkers, like those developed by AMRA, will be an important part of introducing a population health perspective within MSK MRI.

We’re excited to be part of the conversation and hope to see you in Cape Town! If you will be at the conference and want to get in touch, make sure to tune into Per’s session, and feel free to reach out to connect with our team onsite featuring Andrea Robina and Per Widholm, or contact us at [email protected].

We hope to see you there!

06/05/2026

What happens to muscle composition following bariatric surgery?

The AMRA team is heading to Istanbul for the 33rd European Congress on Obesity to share findings from a study using our MRI-based muscle biomarkers to quantify and assess longitudinal changes in muscle composition among adults with obesity undergoing metabolic surgery.

Researchers from AMRA, alongside our collaborators at the University of California San Diego, the University of Wisconsin-Madison, and Regeneron investigated muscle composition changes in 98 participants. The results showed that while surgery leads to an overall reduction in muscle mass, it also improves muscle quality through decreased fat infiltration. Most muscle volume loss occurred within the first 12 weeks and plateaued by one year, with signs of recovery relative to body weight over time.

The study, titled ‘Impact of metabolic surgery on muscle composition: A longitudinal MRI study’ will be shared during an oral presentation by AMRA’s Chief Scientific Officer, Dr. Jennifer Linge, featured as a “Hot Topics” abstract during the T4 Session on May 14th from 11:30 - 13:00.

If you’ll be in Istanbul for ECO 2026, make sure to tune into our presentation and connect with Jennifer Linge, Leanna Kellerman and Nicklas Weman onsite to learn more about our science!

Read more about the study here: https://amramedical.com/what-happens-to-muscle-composition-following-bariatric-surgery-amra-medical-to-share-findings-at-the-33rd-european-congress-on-obesity/

30/04/2026

AMRA Medical is gearing up for the 33rd European Congress on Obesity (ECO 2026) in Istanbul from May 12th-15th!

Our team is looking forward to again contributing to the conversation and sharing our latest findings regarding muscle composition in obesity!

Don’t miss our oral presentation, “Impact of metabolic surgery on muscle composition: A longitudinal MRI study.” Presented by AMRA’s Chief Scientific Officer, Dr. Jennifer Linge, the session will be featured as a “Hot Topics” abstract during the T4 Session on May 14th from 11:30–13:00.

Reach out to Leanna Kellerman and Nicklas Weman via [email protected] if you’re interested in learning more about how AMRA’s MRI-based biomarkers are helping clinical trials assess treatment effects in obesity and metabolic disease. We can’t wait to see you in Istanbul for this important event!

28/04/2026

Are you in Switzerland this week for the 25th BioPharma Clinical Trials Nexus Conference?

Make sure to connect with Leanna Kellerman, Chief Globalization Officer at AMRA Medical, who will be onsite in Zurich!

This event brings together senior leaders across pharma and biotech to drive meaningful dialogue around the future of clinical trials; from innovation in study design to new approaches shaping clinical development.

If you’re attending the Nexus, connect with Leanna to exchange ideas and explore how AMRA’s advanced MRI-based fat and muscle biomarkers can support smarter, more efficient clinical trials.

23/04/2026

New AMRA Research Assessing the Impact of AMC in CKD Published in Clinical Journal of the American Society of Nephrology!

AMRA Medical researchers recently set out to answer the question: does muscle composition identify high-risk individuals with chronic kidney disease? The answer showed that adverse muscle composition (AMC), characterized by low muscle volume z-score and high muscle fat infiltration, is an independent and strong predictor of all-cause mortality in individuals with chronic kidney disease (CKD).

Over a mean follow-up period of 3.6 years, individuals with CKD and AMC showed a markedly increased risk of all-cause mortality, with an unadjusted hazard ratio of 6.17. Importantly, this association remained significant even after adjusting for demographic, lifestyle, and clinical factors, with a hazard ratio of 4.21.

These findings highlight AMC as a clinically meaningful phenotype, enabling broader stratification of high-risk individuals and supporting the value of MRI-based muscle biomarkers in clinical trials across chronic diseases.

Read the full release from AMRA: https://amramedical.com/does-muscle-composition-identify-high-risk-individuals-in-chronic-kidney-disease-new-amra-medical-study-says-yes-reveals-strong-link-to-mortality/

21/04/2026

Job Opportunity!!
We are looking for a temporary replacement for our Office Coordinator, who will be on parental leave during the period June 2026–August 2027. You are responsible for administrative tasks related to workplace wellbeing and maintaining order at our head office in Linköping. You are the main point of contact for office-related matters, both internally and for external partners.

👉 Read more here: https://amramedical.teamtailor.com/jobs/7554215-office-coordinator-till-amra-medical

17/04/2026

What an amazing Day Two we’ve had here at the 3rd Annual GLP-1-Based Therapeutics Summit! The sessions expanded the conversation beyond cardiometabolic disease, highlighting just how quickly the therapeutic horizon for GLP-1s is evolving.

A major theme throughout the day was about exploring the potential of GLP-1-based therapies in areas such as neurodegenerative disease, aging, addiction, and women’s health, reinforcing the growing idea that these therapies may extend their benefit beyond weight loss into new disease areas.

The day concluded with a forward-looking perspective: GLP-1 therapies are no longer confined to diabetes or obesity. Instead, they are emerging as a foundational platform for a new generation of treatments, where personalization and expanded applications will define the next wave of innovation.

“What stood out from this meeting is how the conversation has shifted towards what these therapies can do beyond weight loss and importantly, how well we can measure their effects, " says AMRA’s Chief Globalization Officer, Leanna Kellerman. “This is something that AMRA has kept in mind as we continue to pioneer development of MRI-based methods and measures for metabolic research and beyond, and we couldn’t be more excited about the future of the field after this conference.”

Want to connect with AMRA to learn more about how we’re reshaping MRI-based biomarkers for metabolic disease research? Reach out to us at [email protected].

15/04/2026

AMRA has wrapped up Day One at the 3rd Annual GLP-1-Based Therapeutics Summit here in Boston, and today has made one thing clear: we’ve officially moved beyond the first wave of GLP-1 success into a far more complex and competitive phase of innovation!

Across sessions, conversations centered on combination therapies, expanding into new indications like kidney and liver disease, and unlocking broader clinical impact through more personalized approaches.

Importantly, the discussion on Day One shifted toward how we evaluate these therapies. A key highlight was AMRA’s session, “Reshaping the Standard: MRI Muscle Composition for Treatment Evaluation and Differentiation in Metabolic Disease and Beyond,” presented by CSO Dr. Jennifer Linge. Drawing on nearly two decades of research, the session highlighted how AMRA’s standardized MRI muscle biomarkers enable consistent, interpretable assessment of muscle composition. Central to this was the use of weight- and BMI-invariant muscle volume Z-Scores, which uncover treatment effects independent of body weight. As therapies continue to drive significant weight loss, these insights are becoming critical to understanding true treatment effects, individual response, and opportunities for differentiation across GLP-1 therapies.

Stay tuned to find out what we learn from tomorrow’s highly-anticipated Day Two! If you’re in Boston this week for the Summit and would like to connect with AMRA onsite, reach out to us at [email protected].

Adress

Badhusgatan 5
Linköping
58222

Öppettider

Måndag	09:00 - 17:00
Tisdag	09:00 - 17:00
Onsdag	09:00 - 17:00
Torsdag	09:00 - 17:00
Fredag	09:00 - 17:00

Telefon

+4613162600

Webbplats

http://www.amramedical.com/

Aviseringar

Var den första att veta och låt oss skicka ett mail när AMRA Medical postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Affären

Skicka ett meddelande till AMRA Medical:

Genvägar

Vill du placera din affär längst upp i Hälso- Och Skönhetsföretag-listan i Linköping?

Dela

Typ

Health/Medical/ Pharmaceuticals